Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 2/2016

01-02-2016 | Original Article

Synthesis and evaluation of a new vesamicol analog o-[11C]methyl-trans-decalinvesamicol as a PET ligand for the vesicular acetylcholine transporter

Authors: Yoji Kitamura, Takashi Kozaka, Daisuke Miwa, Izumi Uno, Mohammad Anwar-ul Azim, Kazuma Ogawa, Junichi Taki, Seigo Kinuya, Kazuhiro Shiba

Published in: Annals of Nuclear Medicine | Issue 2/2016

Login to get access

Abstract

Introduction

We focused on the vesicle acetyl choline transporter (VAChT) as target for early diagnosis of Alzheimer’s diseases because the dysfunction of the cholinergic nervous system is closely associated with the symptoms of AD, such as problem in recognition, memory, and learning. Due to its low binding affinity for the sigma receptors (σ-1 and σ-2), o-methyl-trans-decalinvesamicol (OMDV) demonstrated a high binding affinity and selectivity for vesicular acetyl choline transporter (VAChT). [11C]OMDV was prepared and investigated the potential as a new PET ligand for VAChT imaging through in vivo evaluation.

Method

[11C]OMDV was prepared by a palladium-promoted cross-coupling reaction using [11C]methyl iodide, with a radiochemical yield of 60–75 %, a radiochemical purity of greater than 98 %, and a specific activity of 5–10 TBq/mmol 30 min after EOB. In vivo biodistribution study of [11C]OMDV in blood, brain regions and major organs of rats was performed at 2, 10, 30 and 60 min post-injection. In vivo blocking study and PET–CT imaging study were performed to check the binding selectivity of [11C]OMDV for VAChT.

Results

In vivo studies demonstrated [11C]OMDV passage through the blood–brain barrier (BBB) and accumulation in the rat brain. The regional brain accumulation of [11C]OMDV was significantly inhibited by co-administration of vesamicol. In contrast, brain accumulation of [11C]OMDV was not significantly altered by co-administration of (+)-pentazocine, a selective σ-1 receptor ligand, or (+)-3-(3-hydroxyphenyl)-N-propylpiperidine [(+)-3-PPP], a σ-1 and σ-2 receptor ligand. PET–CT imaging revealed inhibition of [11C]OMDV accumulation in the brain by co-administration of vesamicol.

Conclusion

[11C]OMDV selectively binds to VAChT with high affinity in the rat brain in vivo, and that [11C]OMDV may be utilized in the future as a specific VAChT ligand for PET imaging.
Literature
1.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil. Neurology. 2001;57:481–8.CrossRefPubMed
2.
Gauthier S, Lopez OL, Waldermar G, Lones RW, Cummings J, Zhang R, et al. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer’s disease. Int Psychogeriatr. 2010;22:973–83.CrossRefPubMed
3.
McGeer PL. Aging, Alzheimer’s disease, and the cholinergic system. Can J Physiol Pharmacol. 1984;62:741–54.CrossRefPubMed
4.
Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics. J Neurosci Res. 1990;27:576–86.CrossRefPubMed
5.
Efange SM, Garland EM, Staley JK, Khare AB, Mash DC. Vesicular acetylcholine transporter density and Alzheimer’s disease. Neurobiol Aging. 1997;18(4):407–13.CrossRefPubMed
6.
Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Annals of neurology. 1996;40(3):399–410.CrossRefPubMed
7.
Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM, Amaral E, et al. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron. 2006;51(5):601–12.CrossRefPubMed
8.
Schafer MK, Weihe E, Erickson JD, Eiden LE. Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter. J Mol Neurosci. 1995;6:225–35.CrossRefPubMed
9.
Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P 301 S tauopathy mouse model. Neuron. 2007;53:337–51.CrossRefPubMed
10.
Bar BA, Parsons SM. Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4-phenyl[3,4-3H]-piperidino) cyclohexanol. Proc Natl Acad Sci USA. 1986;83:2267–70.CrossRef
11.
Marshall IG, Parsons SM. The vesicular acetylcholine transport system. TINS. 1987;10:174–7.
12.
Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM, Amaral E, et al. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron. 2006;51(5):601–12.CrossRefPubMed
13.
Efange SM, Michelson RH, Khare AB, Thomas JR. Synthesis and tissue distribution of (m-[125I]iodobenzyl)trozamicol ([125I]MIBT): potential radioligand for mapping central cholinergic innervation. J Med Chem. 1993;36:1754–60.CrossRefPubMed
14.
Efange SM, Mach RH, Khare AB, Michelson RH, Nowak PA, Evora PH. [18F]Fluorobenzyltrozamicol ([18F]FBT): molecular decomposition-reconstitution approach to vesamicol receptor radioligands for positron emission tomography. Appl Radiat Isot. 1994;45:465–72.CrossRefPubMed
15.
Mulholland GK, Wieland DM, Kilbourn MR, Frey KA, Sherman PS, Carey JE, et al. [18F]Fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse. 1998;30:263–74.CrossRefPubMed
16.
Sorger D, Schliebs R, Kampfer I, Rossner S, Heinicke J, Dannenberg C, et al. In Vivo [125I]-Iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system. Nucl Med Biol. 2000;27:23–31.CrossRefPubMed
17.
Shiba K, Mori H, Tonami N. Evaluation of radioiodinated (−)-o-iodovesamicol as a radiotracer for mapping the vesicular acetylcholine transporter. Ann Nucl Med. 2003;17(6):451–6.CrossRefPubMed
18.
Shiba K, Nishiyama S, Tsukada H, Ishiwata K, Kawamura K, Ogawa K, et al. The potential of (−)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia. Synapse. 2009;63(2):167–71.CrossRefPubMed
19.
Efange SM, Mach RH, Smith CR, Khare AB, Foulon C, Akella SK, et al. Vesamicol analogues as sigma ligands: molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995;49:791–7.CrossRefPubMed
20.
Rogers GA, Parsons SM, Anderson DC, Nilsson LM, Bahr BA, Kornreich WD, et al. Synthesis, in vitro acetylcholine- storage- blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidineo) cyclohexanol (Vesamicol). J Med Chem. 1989;32:1217–30.CrossRefPubMed
21.
Kozaka T, Uno I, Kitamura Y, Miwa D, Ogawa K, Shiba K. Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT). Bioorg Med Chem. 2012;20(16):4936–41.CrossRefPubMed
22.
Kozaka T, Uno I, Kitamura Y, Miwa D, Azim MA, Ogawa K, et al. Regional brain imaging of vesicular acetylcholine transporter (VAChT) using o-[125I]iodo-trans-decalinvesamicol as a new potential imaging probe. Synapse. 2014;68(3):107–13.CrossRefPubMed
23.
Azim MA, Kozaka T, Uno I, Miwa D, Kitamura Y, Ogawa K, et al. The potential of the vesicular acetylcholine transporter (VAChT) Imaging Using Radiolabeled o-Bromo-trans-decalinvesamicol (OBDV) as a New PET Ligand. Synapse. 2014;68:445–53.CrossRefPubMed
24.
Kawamura K, Shiba K, Tsukada H, Nishimura S, Mori H, Ishiwata K. Synthesis and evaluation of vesamicol analog (−)-o-[11C]methylvesamicol as a PET ligand for vasicular acetylcholine transporter. Annal. Nucl. Med. 2006;20(6):417–24.CrossRef
25.
Shiba K, Yano T, Sato W, Mori H, Tonami N. Characterization of radioiodinated (−)-ortho-iodovesamicol binding in rat brain preparations. Life Sci. 2002;71(13):1591–8.CrossRefPubMed
26.
Samuelsson L, Långström B. Synthesis of 1-(2′-deoxy-2′-fluoro- β-D-arabinofuranosyl)-[methyl-11C]thimine ([11C]FMAU) via a still cross-coupling reaction with [11C]methyl iodide. J Label Compd Radiopharm. 2003;46:263–72.CrossRef
27.
Frey KA, Wieland DM, Kilbourn MR. Imaging of monoaminergic and cholinergic vesicular transporters in the brain. Adv Pharmacol. 1998;42:269–72.CrossRefPubMed
28.
Efange SM. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 2000;14:2401–13.CrossRefPubMed
29.
Mash DC, Zabetian CP. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse. 1992;12:195–205.CrossRefPubMed
30.
David A, McCormick. 1989, Acetylcholine: distribution, receptors, and actions. Section of Neuroanatomy, Yale Univrersity of School of Medicine. 333 Cedar Street, New Haven, CT 06510, USA.
31.
Quirion R, Aubert I, Araujo DM, Hersi A, Gaudreau P. Autoradiographic distribution of putative muscarinic receptor sub-types in mammalian brain. Prog Brain Res. 1993;98:85–93.CrossRefPubMed
32.
Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. The Journal of Neuroscience. 1991;11(10):3218–26.PubMed
33.
Vilaro MT, Mengod G, Palacios JM. Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors. Prog Brain Res. 1993;98:95–101.CrossRefPubMed
34.
Rotter A, Jacobwitz DM. Neurochemical identification of cholinergic forebrain projection sites of the nucleus tegmentalis dorsalis lateralis. Brain Res Bull. 1981;6:525–9.CrossRefPubMed
35.
Jung YW, Van Dort ME, Gildersleeve DL, Wieland DM. A radiotracer for mapping cholinergic neurons of the brain. J Med Chem. 1990;33:2065–8.CrossRefPubMed
36.
Altar CA, Marien MR. [3H]vesamicol binding in brain: autoradiographic distribution, pharmacology, and effects of cholinergic lesions. Synapse. 1988;2(5):486–93.CrossRefPubMed
37.
Weissman AD, Su T-P, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther. 1988;247(1):29–33.PubMed
38.
Waterhouse RN, Mardon K, O’Brien JC. Synthesis and Preliminary Evaluation of [123I]1-(4-Cyanobenzyl)-4-[[(trans-iodopropen-2-yl)oxy]-methyl]piperidine: a novel high affinity sigma receptor radioligand for SPECT. Nucl Med Biol. 1997;24:45–51.CrossRefPubMed
39.
Kawamura K, Ishiwata K, Tajima H, Ishii S. In vivo evaluation of [11C]SA4503 as a PET Ligand for mapping CNS sigma1 receptor. Nucl Med Biol. 2000;27:255–61.CrossRefPubMed
40.
Butcher LL, Oh JD, Woolf NJ. Cholinergic neurons identified by in situ hybridization histochemistry. Prog Brain Res. 1993;98:1–8.CrossRefPubMed
41.
Woolf NJ, Eckenstein F, Butcher LL. Cholinergic projections from the basal forebrain to the frontal cortex: a combined fluorescent tracer and immunohistochemical analysis. Neurosci Lett. 1983;40:93–8.CrossRefPubMed
42.
Woolf NJ, Butcher LL. Cholinergic system in the rat brain: III. Projection from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull. 1986;16:603–37.CrossRefPubMed
Metadata
Title
Synthesis and evaluation of a new vesamicol analog o-[11C]methyl-trans-decalinvesamicol as a PET ligand for the vesicular acetylcholine transporter
Authors
Yoji Kitamura
Takashi Kozaka
Daisuke Miwa
Izumi Uno
Mohammad Anwar-ul Azim
Kazuma Ogawa
Junichi Taki
Seigo Kinuya
Kazuhiro Shiba
Publication date
01-02-2016
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 2/2016
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-1039-6

Other articles of this Issue 2/2016

Annals of Nuclear Medicine 2/2016 Go to the issue

Original Article

FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy

Original Article

The edge artifact in the point-spread function-based PET reconstruction at different sphere-to-background ratios of radioactivity

Original Article

Correlation of 4′-[methyl-11C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with 11C-methionine uptake

Original Article

Current generation time-of-flight 18F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands

Acknowledgements to Reviewers

Acknowledgements to reviewers

Short Communication

Iodine-131 imaging using 284 keV photons with a small animal CZT-SPECT system dedicated to low-medium-energy photon detection